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Abstract: The P2X7 receptor is an ATP-gated cation channel with a still ambiguous role in cancer
progression, proposed to be either pro- or anti-cancerous, depending on the cancer or cell type in the
tumour. Its role in mammary cancer progression is not yet defined. Here, we show that P2X7 receptor
is functional in highly aggressive mammary cancer cells, and induces a change in cell morphology
with fast F-actin reorganization and formation of filopodia, and promotes cancer cell invasiveness
through both 2- and 3-dimensional extracellular matrices in vitro. Furthermore, P2X7 receptor
sustains Cdc42 activity and the acquisition of a mesenchymal phenotype. In an immunocompetent
mouse mammary cancer model, we reveal that the expression of P2X7 receptor in cancer cells, but
not in the host mice, promotes tumour growth and metastasis development, which were reduced
by treatment with specific P2X7 antagonists. Our results demonstrate that P2X7 receptor drives
mammary tumour progression and represents a pertinent target for mammary cancer treatment.
Keywords: P2X7 receptor; cancer cell invasiveness; invadopodia; metastases; antagonists
1. Introduction
The P2X7 receptor (P2X7R) belongs to the family of ionotropic P2X receptors, which function as
ATP-gated cation selective channels that are permeable to Na+, Ca2+ and K+ ions. However, P2X7R
displays several functional and biological specificities differing largely from the other members of
the P2X receptor family [1]. From a pharmacological point of view, a specific feature of P2X7R is
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to be 10–100 times less sensitive to its natural agonist ATP than all other P2X receptors, requiring
millimolar concentrations to show measurable activation while all the others are activated by micromolar
concentrations. In addition, P2X7R is about 10–30 times more sensitive to 2,3-O-(4-benzoylbenzoyl)-ATP
(BzATP), a synthetic ATP analogue, than ATP [1]. A unique functional property of P2X7R is that
upon prolonged or repeated agonist stimulation, it exhibits no desensitisation and instead striking
facilitation or sensitization, a functional property characterized by an increase in the current response
as well as an enhanced agonist sensitivity [2]. This unique functional property results in potentiation
of downstream signalling pathways initiated by P2X7R.
While all other P2X receptors are mainly expressed in the nervous system, such as in neurons and
glial cells, participating in the modulation of synaptic transmission, the P2X7R is mostly characterized
by its predominant expression in immune cells and its critical role in immunity and inflammatory
responses [3]. In the context of cancers, the P2X7R has attracted escalating attention over the past
years. It has been reported that P2X7R is overexpressed in many different types of tumours, specifically
in miscellaneous carcinomas [4], with the possible exception of cervical and endometrial cancers, in
which it was intriguingly down-regulated [5,6]. Many studies provide evidence to show that P2X7R
activity or activation protects cells from apoptosis [7], promotes cancer cell trophic activity and primary
tumour growth [8,9] and stimulates cancer cell migration or invasion [10–15]. These studies thus
favour a pro-cancerous role for P2X7R and propose that P2X7R antagonists are promising anticancer
drugs [16]. In contrast, several other studies demonstrate that P2X7R induces cancer cell death
upon ATP stimulation [17] or even enhances anti-tumour immune responses from the host organism,
thus supporting the P2X7R to be anti-cancerous [18,19]. The role of P2X7R in cancer promotion
appear to depend on multiple factors, including the type of cancers or tumours, the level of expression
or activation of the receptor, the cell type considered (cancer cells vs. immune cells), the level
of immune cell infiltration within the tumour and also the phase in the carcinogenic progression.
Therefore, it remains unclear whether it would be beneficial, or detrimental, to antagonize P2X7R for
anticancer purposes, and this needs to be addressed in specific cancer models.
In breast cancer, it has been shown that the P2X7R is overexpressed [20], fully functional
and promotes cancer cell invasiveness, both in vitro and in an in vivo zebrafish model [12,21,22].
Moreover, P2X7R was demonstrated to induce the release of active proteolytic cysteine cathepsins [12],
a finding that further suggests the involvement of P2X7R in the “mesenchymal mode” of invasion,
in which cells remodel the extracellular matrix (ECM), by forming particular cellular structures that
are enriched in F-actin and protrusive into the ECM called “invadopodia”, and using such proteolytic
activity, generate their pathway [23].
In this study, we assessed the role of P2X7R in mammary cancer cells in determining the invasive
properties, using both 2- and 3-dimensions models, more specifically, the invadopodial activity, and
characterized the involvement of P2X7R in the acquisition of a mesenchymal phenotype in vitro.
We also assessed the consequences of P2X7R expression in primary tumour growth and metastatic
spreading in vivo. This study further aimed to clarify the relevance of pharmacological intervention
using specific P2X7R antagonists in the treatment of mammary cancers. For this purpose, we developed
an orthotopic, syngeneic and immunocompetent mammary cancer model in BALB/cJ mice, and
studied the role of P2X7 receptor, expressed or not in 4T1 mammary cancer cells (using genetically
engineered cells) or in the host organisms (wild-type P2rx7+/+ versus knock-down P2rx7−/− mice).
Our results unequivocally demonstrate that P2X7R is functionally expressed in mammary cancer cells
and its activation promotes the acquisition of a mesenchymal phenotype and enhances invadopodial
activity. Furthermore, we provide compelling evidence to indicate that the P2X7R expressed in
mammary cancer cells but not in the host organism plays a key role in primary tumour growth
and metastatic development, which are significantly attenuated by treatment with specific P2X7R
antagonists. These findings support that the P2X7R in mammary cancer cells drives mammary tumour
progression and represents a pertinent target for mammary cancer treatment.
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2. Results
2.1. P2X7R Expression Promotes Mammary Cancer Cell Invasiveness
In this study, we aimed at assessing the potential role of P2X7R in mammary cancer progression
in an immunocompetent mouse model. Therefore, we investigated the expression and activity of
P2X receptors in the 4T1 mammary cancer cell line, originating from the BALB/cJ mouse strain [24].
As shown in Figure 1a, 4T1 cells expressed mRNA transcripts for P2X2, P2X3, P2X4 and P2X7. A weak
band can be visualized for P2X5. The functionality of these receptors at the plasma membrane of cancer
cells were assessed using the patch-clamp recording technique. Stimulating the cells with 10 µM ATP,
a concentration that would activate all P2X receptors with the exception of P2X7R, did not produce any
measurable current. However, exposure to 5 mM ATP triggered inward, non-desensitizing, facilitating
currents (Figure S1a) that were inhibited by treatment with A438079, a specific competitive P2X7
antagonist (Figure 1b). These results suggest that 4T1 cells mainly express functional P2X7R, while the
other P2X receptors (P2X2 P2X3, P2X4 and P2X5) would be either not expressed at the protein level or
not functional. To further characterize the ATP-induced currents, we constructed the ATP dose-current
response relationship curve (Figure 1c) that yielded the concentration evoking 50% of the maximal
current response (EC50) to be 4.3 ± 0.2 mM (n = 5–6 cells), consistent with the expression of the mouse
P2X7R. We further used Fura2 fluorimetry to monitor the changes in intracellular Ca2+ levels in 4T1
cells in response to ATP (Figure S1b) or BzATP stimulation (Figure 1d). Both ATP and BzATP induced
a biphasic increase in intracellular Ca2+ levels in cells incubated in extracellular Ca2+-containing
solutions, with a transient component followed by a long-lasting one. The long-lasting Ca2+ increase
was significantly reduced in the presence of A438079 or AZ10606120, a specific non-competitive P2X7R
antagonist (Figure 1e), supporting P2X7R-mediated Ca2+ entry. In addition, the long-lasting, but not
the transient, component was largely abolished in extracellular Ca2+-free solutions (Figure 1d,e, Figure
S1b). Under these conditions, ATP/BzATP-induced intracellular Ca2+ increases were not affected
by treatment with A438079 or AZ10606120, thus indicating that they are mediated by activation of
G-protein coupled P2Y receptors. The P2Y11 receptor is known to be sensitive to both ATP and
BzATP and coupled to intracellular Ca2+ release. The P2Y11 receptor was reported in cancer cells [25].
BzATP-induced intracellular Ca2+ increase in Ca2+-free solutions was attenuated by treatment with
NF340, a P2Y11 selective antagonist (Figure S1c), in support of the role of the P2Y11 receptor in
mediating ATP/BzATP-induced transient Ca2+ increase in 4T1 cells.
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Figure 1. P2X7R is functional in 4T1 mouse mammary cancer cells and drives cell invasiveness.
(a) RT-PCR analysis of P2X mRNA expression. (b) Representative whole-cell patch clamp recordings of
ATP-induced currents. Membrane potential was held at −60 mV. While 10 s application of 10 µM ATP
(left) evoked no detec current, application of 5 mM ATP produced a non-desensitizing current that was
reduced by treatment with 10 µM A438079 (right). (c) Recordings of inward currents from one cell in
response to 10 s applications of increasing concentrations of ATP (0.3, 1, 3, 5 and 10 mM) (left), and
mean ATP dose-response curve, with currents expressed as a ratio of the maximum current obtained
with 10 mM ATP (right). The solid line shows fit to Hill equation. (d) Changes in intracellular Ca2+
levels, indicated by the ratio of Fura2 fluorescence intensity induced by excitation at 340 and 380 nm
(F340/380), by exposure to 300 µM BzATP in cells under control conditions (black traces) and cells treated
with 10 µM A438079 (red traces) in extracellular Ca2+-containing solutions (left) or Ca2+-free solutions
(right). These data are averaged from four independent experiments. There is statistically significant
difference in BzATP-induced Ca2+ responses between control and A438079-treated cells in the presence
of extracellular Ca2+ at p < 0.001, but no significant difference in the absence of extracellular Ca2+, using
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two-way ANOVA and Dunn’s Multiple Comparison post hoc test. (e) BzATP-induced Ca2+ responses
in control cells (vehicle, black traces) and cells treated with 300 nM AZ10606120 (blue traces) in the
presence of 3 mM extracellular Ca2+ (left) or in the absence of extracellular Ca2+ (right), using similar
protocols as in d. These data are averaged from three independent experiments. There is a statistically
significant difference in BzATP-induced Ca2+ responses between control and A438079-treated cells in
the presence of 3 mM extracellular Ca2+ at p < 0.001, but no significant difference in the absence of
extracellular Ca2+, using two-way ANOVA and Dunn’s Multiple Comparison post hoc test. (f) Cell
viability after exposure to increasing concentrations of ATP (from 0.03 to 3 mM) for 24 h without or
with treatment with 10 µM A438079, expressed as % of that under control conditions (vehicle). Results
are from four independent experiments. ATP induced a statistically significant cell viability reduction
compared to control conditions at * p < 0.05, ** p < 0.01 and *** p < 0.0001, but A438079 treatment
had no significant effect on ATP-induced reduction in cell viability, using Student’s t-test. (g) Cell
viability after exposure to increasing concentrations of BzATP (from 0.01 to 1 mM) for 24 h, expressed
as % of that under control condition (vehicle). Results are from four independent experiments. BzATP
induced no significant reduction in cell viability. (h), 4T1 cell invasiveness, assessed using trans-well
invasion inserts after 24 h in the absence or presence of 300 µM BzATP, in cells transfected with control
siRNA (siCTL) or P2X7R-specific siRNA (siP2X7). Results from six independent experiments expressed
relative to the siCTL condition, in the absence of BzATP stimulation (CTL). ** indicates a statistically
significant difference at p < 0.01 when comparing siCTL/BzATP to siCTL/CTL, using Mann-Whitney
Rank Sum Test. NS stands for no statistical difference. (i) 4T1 2D-cell invasiveness was assessed over
24 h using trans-well invasion inserts in the absence or presence of BzATP (300 µM), and in the absence
or presence of P2X7 antagonist A438079 (10 µM). Results are from 4–6 independent experiments and are
expressed relatively to the control condition (CTL), in the absence of BzATP and of A438079. * indicates
a statistically significant difference at p < 0.05 when comparing BzATP treatment to CTL, using Wilcoxon
Signed Rank Test. (j) 4T1 3D-cell invasiveness was assessed over 72 h. The left image shows cancer cell
spheroid morphology assessed before (T = 0 h) or after treatment (T = 72 h) in control condition (vehicle)
or with BzATP (300 µM) in the absence or presence of A438079 (10 µM). Scale bar, 100 µM. On the right
side is the summary of assessment of the spheroid circularity from 14–20 independent experiments.
* indicates a statistically significant difference at p < 0.05 using Dunn’s Multiple Comparison Test.
To explore the role of the P2X7R in cancer cell biology, we first assessed the effects of increasing ATP
concentrations, from 0.03 to 3 mM, on 4T1 cell viability. As shown on Figure 1f, ATP significantly reduced the cell
viability at all doses tested, which was not prevented by treatment with A438079. These results largely ruled out
the participation of P2X7R in such an effect and suggest likely involvement of other P2 receptors or the receptors
for adenosine, the major product of ATP hydrolysis, in the reduction of cell viability. This detrimental effect on cell
viability was not observed when using BzATP as an agonist (Figure 1g). Therefore, to avoid any non-specific effect
related to the activation of another purinergic signalling pathway, BzATP was the only agonist used in all the
following experiments to stimulate the P2X7R and assess its role in the regulation of cancer cells. The participation
of P2X7R in 4T1 cell invasiveness was first assessed in a 2-dimensional (2D) model using invasion filters covered
with a film of Matrigel™, as an extracellular matrix (Figure 1h,i). In cells transfected with a null-target or control
siRNA (siCTL), BzATP enhanced cancer cell invasiveness by a median factor of 1.95. Such a stimulatory effect
was not observed in cells transfected with a siRNA specific for P2rx7 gene (siP2X7) to reduce P2X7R expression
(68.4 ± 1.6% (n = 6) assessed by RT-qPCR) (Figure 1h). Furthermore, BzATP-induced increase in invasiveness
in non-transfected cells was prevented by treatment with A438079 (Figure 1i). We then assessed the effect of
stimulating P2X7R on cancer cell invasiveness, using spheroids composed of 4T1 cells that were grown in a 3D
matrix of Matrigel™ for 72 h (Figure 1j). 4T1 cells are very cohesive cells, tending to invade in a collective mode,
rather than in an individual mode. Therefore, we measured the circularity index of spheroids, which is inversely
correlated to the invasiveness, under different conditions. As shown in Figure 1j, exposure to BzATP reduced the
spheroid circularity, indicating a gain in invasiveness, and BzATP-induced reduction of circularity was prevented
by treatment with A438079. MDA-MB-435s human melanoma cancer cells were used as very aggressive human
cancer cells, and P2X7R was shown to participate in determining the invasive capacities of these cells [11,12].
To compare mechanistic insights with those identified in mouse mammary 4T1 cancer cells, we performed similar
experiments using spheroids composed of MDA-MB-435s cells. Under the same conditions, MDA-MB-435s cells
tended to invade matrices in an individual cell mode (Figure S2a) and exposure to BzATP increased the maximal
distance of matrix invasion, which was also prevented by treatment with A438079 (Figure S2b). Collectively,
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these results indicate that P2X7R activation promotes cancer cell invasiveness, regardless of the mode of invasion
(collective vs. single cell invasion), in both 2D and 3D models.
2.2. P2X7R Participates in the Acquisition of a Mesenchymal Cancer Cell Phenotype
Invadopodia are key structures of cancer cell invasiveness, involved in extracellular matrix (ECM) remodelling.
Therefore, we analysed the ECM digestive activity of cancer cells grown on a planar matrix of Matrigel™ containing
DQ-BSA as a fluorogenic substrate for proteases. Immunofluorescence imaging identified that P2X7R proteins
were strongly co-localized with the matrix proteolysis (Figure 2a) in both mouse 4T1 (Pearson’s r = 0.64) and human
MDA-MB-435s (Pearson’s r = 0.62) cancer cells. Since invadopodia are cancer cell structures that are protrusive into
ECM, it is possible to isolate invadopodia-enriched fractions, from cytosolic or membrane fractions, coming from
cancer cells grown on a thick matrix composed of gelatin [26]. Figure 2b shows that P2X7R proteins are present in
the invadopodia fraction from 4T1 cells, characterised by the presence of the invadopodia markers, cortactin, focal
adhesion kinase (FAK) and cathepsin B (Cath B). Similar results were obtained with human MDA-MB-435s cells
(Figure S3a). Invadopodial activity can be characterised by focalized areas of ECM degradation co-localised with
F-actin condensations. To assess a possible regulation of the invadopodial activity by P2X7R, 4T1 cells were grown
on a planar matrix of Matrigel containing DQ-BSA, and F-actin was labelled (Figure 2c). Areas corresponding
to the co-localization of F-actin condensation areas and focal spots of DQ-BSA proteolysis were identified and
quantified per cell. Stimulating the cells with BzATP increased the surface of degradation spots, and this was
prevented by treatment with A438079 (Figure 2d), whereas the number of invadopodial structures (degradation
spots) per cell remained unchanged (Figure 2e). Similar results were obtained with human MDA-MB-435s cells
(Figure S3b–d). These results strongly suggest that P2X7R activity enhances the proteolytic activity of individual
invadopodia. In MDA-MB-435s human cancer cells, it is known that P2X7R activity facilitates release of multiple
cathepsin isoforms including Cath B into the extracellular compartment [12]. We wondered whether P2X7R
activation resulted in a similar effect in 4T1 cells. Indeed, exposure to BzATP increased the amount of mature Cath
B in the supernatants of 4T1 cells by 2.12 ± 0.65 fold, and this was prevented by treatment with A438079 (Figure 2f).
The ECM digestive activity and the presence of invadopodia are specific characteristics of cancer cells
showing a “mesenchymal phenotype” [27]. In this phenotype, engaged cells display an elongated fibroblast-like
morphology, with a rear-to-front cell polarity, formation of lamellopodia at the leading edge and multiple filopodial
structures around the cells. Filopodia are F-actin enriched thin structures allowing attachment to the matrix.
As shown in Figure 3a, stimulation of 4T1 cells with BzATP induced a rapid change in cell morphology with a
remodelling of F-actin cytoskeleton. Cancer cells appeared to be more elongated and the lamellopodia readily
visualized. Time-lapse microscopy imaging (Videos S1–S4) also showed that exposure to BzATP increased the
number of filopodial structures per cell, which was prevented by treatment with A438079 (Figure 3b). Of notice,
treatment with A438079 alone was without effect on the number of filopodia. However, exposure to BzATP did
not affect the velocity to form and extend filopodia (Figure 3c). It is known that the cytoskeleton remodelling and
the acquisition of invasive phenotypes in cancer cells are orchestrated by members of the Rho-GTPase family,
particularly, Cdc42 that has an important role in cancer cell invasion, acquisition of a mesenchymal phenotype,
and formation of invadopodia [28]. Interestingly, exposure to BzATP increased the level of the active, GTP-bound
form of Cdc42, with no effect on RhoA and Rac1, and such an effect on Cdc42 was abrogated by treatment with
A438079 (Figure 3d). To further study the participation of P2X7R in the epithelial-to-mesenchymal transition
(EMT), we assessed the effect of stimulating 4T1 cancer cells with BzATP on the expression of genes associated
with the mesenchymal (SNAI1, ZEB1, TWIST) or the epithelial (ZO1, CDH1) phenotypes. Exposure to BzATP,
while inducing no change in the expression of SNAI1, ZEB1 and TWIST, repressed the expression of ZO1 encoding
for the epithelial tight junction protein Zonula occludens-1. Stimulating cells with BzATP had no effect on
the expression of CDH1, encoding for E-cadherin (Figure 3e). Protein expressions of the mesenchymal marker
vimentin and epithelial marker E-cadherin were also assessed. Vimentin protein level was not modified upon
P2X7 stimulation. A trend for a decrease expression of E-cadherin was observed under BzATP treatment, but was
not prevented by A438079, suggesting that there was no P2X7-attributable effect (Figure 3f).
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Figure 2. P2X7 receptor promotes invadopodial activity of extracellular matrix degradation. (a) 4T1
mouse mammary and MDA-MB-435s human cancer cells were grown on Matrigel™ containing DQ-BSA
as a fluorogenic substrate for proteases, emitting red fluorescence when degraded. P2X7 receptor was
immunodetected using a rabbit primary antibody against P2X7 protein and a secondary ant-rabbit IgG
antibody conjugated to AF488. The right panel shows the fluorescence values for the two channels
at the locations indicated by a blue arrow. Scale bar, 100 µM. (b) Invadopodia entrapped into a
2%-gelatin matrix were fractionated and separated from cytosol and membranes-enriched fractions.
The quality of the fractions was assessed by western blotting after SDS-PAGE, using cytosolic (HSC70),
membrane (caveolin-1, β-adaptin) and invadopodia (cathepsin B, cortactin, focal adhesion kinase)
markers. P2X7 proteins were found to be present in the membrane fractions and enriched in the
invadopodia fraction. This figure is representative of 5 independent experiments. The full image
blots can be found in Figure S5. (c) The invadopodial activity was assessed as being F-actin foci
(green labelling, phalloidin-488) co-localised with focused proteolytic activities (red labelling, DQ-BSA
proteolysis) from 4T1 cells grown for 24 h on Matrigel™ containing DQ-BSA in control condition
(vehicle), or stimulated with 300 µM BzATP, in the presence and absence of 10 µM A438079. “Coloc”
indicates co-localization of degradative activity and F-actin foci and appears as white pixels. Scale bar,
50 µM. (d) The number of degradation areas per cell was counted in 20 images, from five independent
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experiments.* indicates a statistically significant difference at p < 0.05 using Dunn’s Multiple Comparison
Test. NS stands for no statistical difference. (e) The number of invadopodia (identified as being F-actin
foci colocalized with matrix degradation spots) was counted per cell in the same experiments as in d.
There was no significant difference among the four treatment conditions. (f) Western blot analyses for
cathepsin B (Cath B) in concentrated cell-free supernatants of 4T1 cells after 24 h treatment with BzATP
(300 µM) in presence or not 10 µM A438079. Pro- and mature forms of Cath B were detected (top).
β-actin was detected in corresponding cell lysates and was used as an internal control. Amounts of
released mature forms of Cath B in supernatants of 4T1 cells in the three experimental conditions were
analysed, from five independent experiments and expressed as a proportion of β-actin in corresponding
cells. Box plots indicate median, first and third quartile and the mean is indicated as a square. * indicates
a statistically significant difference at p < 0.05 using Dunn’s Multiple Comparison Test. The full image
blots can be found in Figure S5.
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time indicated. Rapid morphological changes appear as rapidly as after 6 min stimulation. Scale bar,
25 µm. (b) The number of new filopodia per cell was counted per hour in cells transfected with
the LifeAct plasmid and studied in the presence of 300 µM BzATP, in the presence or absence of
10 µM A438079. * indicates a statistically significant difference at p < 0.05 using Dunnett’s Multiple
Comparison Test. (c) The velocity of filopodia to form and extend (in µM/min) was measured in
the same experiments as in (b). There was no significant difference among the four experimental
groups. (d) On the left side, representative western blots show total and active GTP-bound forms of
Cdc42, RhoA, and Rac1 pulled down by GST-RBD in 4T1 cells in control conditions or stimulated
for 30 min with 300 µM BzATP, in the presence and absence of 10 µM A438079. His-tagged proteins
are used as positive controls for the quality of the pull-down experiment. On the right side, graphs
show quantifications of GTP-bound RhoGTPases (active form), normalized to total protein level,
and expressed relatively to that of the control condition (vehicle). Results are from 4–7 independent
experiments. * indicates statistically significant difference at p < 0.05, using Mann-Whitney rank sum
test. NS stands for no statistical difference. The full image blots can be found in Figure S7. (e) mRNA
expression levels of P2rx7, SNAI1, ZEB1, TWIST1, ZO1 and CDH1 assessed by RT-qPCR in 4T1 cells
stimulated by 300 µM BzATP for 24 h and expressed relatively to the GUSB reference gene and as
ratios to the expression levels in control condition without BzATP (n = 9–11 independent experiments).
SNAI1 was significantly higher, and ZO1 was significantly lower after BzATP treatment compared to
control condition at * p < 0.05, using Mann-Whitney rank sum test. (f) representative western blots
(from four independent experiments) show vimentin and E-cadherin expression in 4T1 cells in control
conditions or stimulated for 24h with 300 µM BzATP, in the presence and absence of 10 µM A438079.
There was no significant effect. The full image blots can be found in Figure S7.
Taken together, these results support the P2X7R as a strong promoter of invadopodial activity that participates
in maintaining a mesenchymal aggressive phenotype in cancer cells without being critical to the induction of EMT.
2.3. P2X7R Enhances Mammary Tumour Growth and Metastasis Development and Is a Target for Anticancer
Treatment
In order to assess the role of P2X7R in mammary tumour growth and metastatic progression, we genetically
modified 4T1 cells for its expression, using the CRISPR/Cas9 gene-editing technique, generating three cell lines,
two of which were named Crispr#1 and Crispr#2 with the P2rx7 knocked-down with an efficacy of >95%, and one
cell line named CTL expressing the P2rx7 gene at a level similar to that in the parental 4T1 cells (Figure 4a). As a
result, the Crispr#1 and Crispr#2 cell lines displayed a reduced invasiveness capacity compared to the CTL cell line
and, furthermore, exposure to BzATP induced no potentiation of cell invasiveness (Figure 4b). Both Crispr#1 and
Crispr#2 cell lines demonstrated a slight increase in proliferation (by a median factor of 1.32 and 1.33, respectively
Figure 4c) and in cell adhesion (by a median factor of 1.19 and 1.15, respectively; Figure 4d) relative to CTL cells,
under basal conditions, i.e., without agonist exposure. These three cell lines demonstrated a luciferase activity
that was comparable to that of parental 4T1 cell line (Figure S4a), allowing their use for in vivo experiments.
In order to decipher the role of P2X7R expressed by the cells of an organism hosting a mammary tumour, most
importantly the immune cells, on primary tumour growth and metastasis development, we implanted CTL cells
with two cell density (1 × 106 or 1 × 104 cells) in the fifth mammary fat-pad of either wild-type (P2rx7+/+) or
knock-out (P2rx7−/−) BALB/cJ mice (Figure 4e). Surprisingly, regardless of the density of cancer cells implanted,
there was no difference in either the mammary tumour growth (Figure 4f,h) or in the metastatic development
(Figure 4g,i) between the P2rx7+/+ and P2rx7−/− mice. These results indicate that in this model, the expression
of P2X7R in host cells does not interfere with mammary tumour progression. Next, we assessed the role of the
P2X7R expressed in cancer cells (Figure 4j). Genetic depletion of P2X7R expression in 4T1 cells strongly reduced
mammary tumour growth in wild-type mice (Figure 4k) and also, most probably as a consequence of primary
tumour reduction, markedly inhibited the development of metastatic foci (Figure 4l). The knock-down of P2rx7
expression in Crispr#1 and Crispr#2 cells remained stable in the whole duration of the in vivo experiments (Figure
S4b) as well as in primary tumours generated by these cells (Figure S4c). These results indicate that P2X7R in
cancer cells (Figure 4c) rather than P2X7R in host animals (Figure 4f–i) promotes mammary tumour progression.
Finally, we wondered whether treatment of mice bearing established mammary tumours with specific P2X7
antagonists would be effective to slow down the tumour growth.
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CTL cell line without BzATP (n = 5–8 independent experiments). * indicates a statistically significant
difference from CTL/no BzATP condition at p < 0.05, ¤ indicates a statistically significant difference
from CTL/BzATP at p < 0.05, using Dunn’s Multiple Comparison Test. NS, stands for no statistically
significant difference. (c) Cell proliferation over 4 days of CTL, Crispr#1 and Crispr#2 cell lines in the
absence of 300 µM BzATP, expressed relatively to the CTL condition. Results are from 6–10 independent
experiments. * indicates a statistically significant difference from CTL at p < 0.05 using Dunn’s Multiple
Comparison Test. (d) Cell adhesion of CTL, Crispr#1 and Crispr#2 clones, expressed relatively to CTL.
Results are from 10 independent experiments. * indicates a statistically significant difference from CTL
at p < 0.05 using Dunn’s Multiple Comparison Test. (e–i) In vivo mouse experiments testing the effect
of P2rx7 gene expression in host mice on primary tumour growth and metastasis development, with
two numbers of cancer cells implanted. (e) Top, cartoon describing the experimental procedure, in
which CTL cells, derived from 4T1-Luc expressing P2rx7 gene, were implanted to the fifth mammary fat
pad of 6 weeks-old female wild-type BALB/cJ (P2rx7+/+) or P2X7 knock-out BALB/cJ (P2rx7−/−) mice.
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Bottom, representative bioluminescent images of a wild-type mouse, on 14 and 35 days after cell
implantation, identifying primary tumours as well as metastatic foci. (f) Primary mammary tumour
growth in wild-type BALB/cJ (P2rx7+/+, n = 8) or P2X7 knock-out BALB/cJ (P2rx7−/−, n = 8) mice as a
function of time following the implantation of 1 × 106 CTL cells on day 0. (g) Analysis of the number
of metastases per mouse, identified at necropsy, in the experiment described in (f). NS stands for no
statistical significant difference. (h) Primary mammary tumour growth in wild-type BALB/cJ (P2rx7+/+,
n = 8) or P2X7 knock-out BALB/cJ (P2rx7−/−, n = 8) mice as a function of time following the implantation
of 1 × 104 CTL cells on day 0. (i) Analysis of the number of metastases per mouse, identified at necropsy,
in the experiment described in (h). NS stands for no statistically significant difference. (j–l) In vivo
mouse experiments assessing the role of P2rx7 gene expression in mammary cancer cells on primary
tumour growth and metastasis development. (j) Cartoon describing the experimental procedure, in
which CTL (P2rx7+/+), Crispr#1 or Crispr#2 (both knock-down for the P2rx7 expression) cells were
implanted to the fifth mammary fat pad of 6 weeks-old female wild-type BALB/cJ (P2rx7+/+) at a
density of 1 × 104 CTL cells per mouse (8 mice per group). (k) Primary mammary tumour growth in
wild-type BALB/cJ (P2rx7+/+) as a function of time following the implantation of CTL, Crispr#1 or
Crispr#2 cells on day 0. *** indicates a statistically significant difference from the CTL group at p < 0.001
using two-way ANOVA. (l) Analysis of the number of metastases per mouse, in the three experimental
groups, identified at necropsy, in the experiment described in (j). * indicates a statistically significant
difference from the CTL group at p < 0.05 using Dunn’s Multiple Comparison test.
Therefore, we injected intraperitoneally wild-type mice with A438079, AZ10606120 or vehicle as a control,
when primary tumours reached a minimal size of 80 mm3 (Figure 5a). The results indicated a tendency for
a reduction in tumour growth in mice treated with either P2X7 antagonist (Figure 5b). We further analysed
these results using a Gompertz mathematical model applied to tumour growth (Figure 5c–e). Estimated mean
(inter-individual standard deviation) of model parameters were kgrowth = 0.64 day-1 (39%), Vmax = 1.620 mm3
(64%), EFF = 0.52 (82%) and γ = 0.17 (–). Such analysis indicates that the tumour volume in the vehicle group
doubled in a mean time of 0.64 day and the mean maximum tumour volume was 1.620 mm3 (Figure 5c).
Treatment with A438079 (Figure 5d) or AZ10606120 (Figure 5e) led to a massive reduction in tumour growth by a
factor of 2 (p < 10−10). There was no difference between treatments with these two antagonists (p = 0.08), even if a
trend toward a better efficacy was observed for treatment with AZ10606120. In addition, Vmax was significantly
higher in the group treated with AZ10606120 (p = 0.0065), which may not be due to treatment itself, but rather
due to between-subject variability. There was no statistically significant difference in the metastatic colonisation
(Figure 5f). Treatment with AZ10606120 resulted in a significant increase in the survival rate (p = 0.0464, Figure 5g),
and a trend for an improved survival rate was noticed in group treated with A438079. Taken together, these
results consistently demonstrate that the P2X7R in mammary cancer cells rather than in host cells (i.e., mainly
immune cells) is critical in driving mammary tumour growth and metastasis development and is a pertinent
target for anticancer treatment.
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3. Discussion
The acquisition of invasive capacities by cancer cells represents a critical mechanism in the cancer progression
and metastasis that significantly impact the survival of cancer patients. Currently, there is no specific treatment
for preventing cancer cell spreading from the primary tumour or preventing metastases appearance. At the
cellular level, several modes of cancer cell migration and invasiveness have been described, both in in vitro and
Cancers 2020, 12, 2342 13 of 23
in vivo models. Among these are the “amoeboid” and the “mesenchymal” modes, that could be identified in both
collective and individual cell invasions [29]. Even though these modes of invasion could be more characteristic of
some cancer types or subtypes, cancer cells do not necessarily stay or are engaged in a specific one. The most
aggressive cells often have the ability to switch from one mode to the other, depending on biological, physical
and chemical conditions and constrains of the microenvironments [30]. Whatever the mode of invasion, being
individual or collective, the capacity of degrading extracellular matrices that determines the dissemination rate
of cancer cells critically depends on the activities of proteases, such as matrix metalloproteinases (MMP) and
cathepsins. This capacity to invade extracellular matrices with a proteolytic degradation was initially described
as being a feature of mesenchymal cancer cells. Mesenchymal cancer cells display an elongated fibroblast-like
morphology, with a rear-to-front lamellopodial cell polarity, and harbour multiple cell-matrix adhesions, such
as filopodial structures. The degradation of the ECM is recognized to be performed by invadosomal structures,
which are F-actin-rich and protrusive into the ECM and responsible for its proteolysis through recruiting both
membrane-associated and extracellularly-released soluble proteases [23,27].
Extracellular ATP is known to be important in the regulation of differentiation and activation of multiple cell
types, under physiological conditions and also under pathological conditions. Over the past few years, ATP-induced
purinergic signalling has attracted considerable attention in the field of oncology [4,31]. Indeed, ATP and other
nucleotides have been demonstrated to be present in high concentrations in the tumour microenvironments,
owing to the active release of ATP from cancer cells and to cell necrosis in the hypoxic halo of solid tumours [32,33].
When released in the extracellular compartment, ATP activates plasma membrane purinergic P2 receptors and
downstream signalling pathways, which are well documented in different cell types in the tumour, such as
cancer cells of course and also immune cells, fibroblasts and endothelial cells. Obviously, the consequences
on tumour and disease progression could be drastically opposite, depending on the cell type considered, and
therefore it is indispensable to develop a clear understanding of the diseases as a whole. The P2X7R is a very
intriguing receptor, which has been demonstrated to be upregulated in multiple cancer types [4], but its clear
involvement in carcinogenesis or cancer progression is still debated. Because the over-stimulation of P2X7R,
either in dose or in duration, is known to induce cell death [34], several studies postulated that it might be
non-functional in proliferating cancer cells [20,35]. It was even proposed that stimulating its activity in cancer
cells would induce their death and could represent therapies for treating cancers [36]. However, multiple
studies demonstrated that the P2X7R is expressed and functional in cancer cells and that its basal activity or
its external stimulation with biologically relevant concentrations of ATP support cancer cell growth, migration
and invasion [12,13,37], and tumour growth [9,14]. In these models, pharmacological antagonism of P2X7R
appeared to be effective in reducing cancer progression, suggesting that targeting P2X7R could represents a novel
opportunity for anticancer treatments.
It is now clearly established that the ATP concentration can reach mM in the necrotic areas of solid tumours.
Such massive necrosis, which provides the large amount of ATP required to activate the P2X7R, mainly occurs in
the inner core of the tumour (e.g., being ischemic and hypoxic) with a decreasing gradient toward the outer part
of the tumour. The outer part is involved in local invasion and subsequent metastasis. Under such conditions,
it is likely that excessive concentration of ATP in the necrotic core induces cancer cell death, while a moderate
concentration of ATP present at the edge of the growing tumours stimulates invasion, through activating the
P2X7R in cancer cells, as proposed in the “run or die” hypothesis [16]. Also, it is not well understood but it may
be important for further studies to assess the P2X7R expression within the tumour and compare the expression
level in the inner core and the outer layer of the tumour.
On the other hand, the important role of P2X7R in the immune responses is well established [3]. Its expression
and activity in cells from the host organism of a tumour might interfere with tumour progression. Importantly, its
role in tumour-associated dendritic cells for the presentation of tumour antigen to CD4+ lymphocytes, and its role
in anti-tumour immune responses were demonstrated [18,38]. Therefore, it was questioned whether P2X7R had a
real role in cancer progression, as well as whether using P2X7 antagonists was pertinent and useful for anticancer
treatment. In a very nice study, Adinolfi and collaborators [39] demonstrated that, when expressed in mouse
melanoma or colon cancer cells subcutaneously inoculated to P2X7R-deficient mice, P2X7R strongly promoted
tumour growth and metastatic dissemination. However, both primary tumour growth and metastases were
reduced in P2X7R-expressing wild-type mice because of a P2X7R-dependent anti-tumour immune response [39].
Another study, performed in the context of colon cancer, also supports an important role for P2X7R in anti-tumour
immune response. In this study, Hofman and collaborators [40] showed that pharmacological antagonism or
genetic silencing of the P2X7R altered immune cell infiltration and increased tumour incidence in a mouse model
of colitis. Therefore, from these studies it appeared that the use of P2X7 antagonists for anti-cancer treatment might
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be deleterious and could lead to opposite tumour-promoting effects. Melanoma and colon cancer development
and progression are known to be highly dependent on the immune and inflammatory system [41,42]. For other
cancers such as mammary cancer, the question is still open, and the relative participation of P2X7R expressed
by cancer cells or host cells might be different and should be specifically assessed. Breast cancer is the primary
cause of death by cancer in women worldwide and patients mostly die because of metastases appearance and
development [43]. Breast tumours are also highly heterogeneous and there are four major molecular subtypes
differing for their prognostic and treatments: Luminal A, Luminal B, HER2-enriched and Triple negative/basal-like.
Triple negative/basal-like tumours are often very aggressive and have a poorer prognosis compared to the
ER-positive subtypes (luminal A and luminal B tumours) [44].
In this study, we have examined 4T1 mouse mammary cancer cells, which are a model of triple-negative
mammary tumours. We demonstrated that the P2X7R is functional in 4T1 cancer cells and that its activation
with natural (ATP) or synthetic (BzATP) agonists induces typical facilitating inward currents and increases in
intracellular Ca2+ levels. Its stimulation did not seem to induce cell death, even though the genetic silencing of the
P2rx7 gene led to a slight increase in the proliferation rate, and instead importantly enhanced cell invasiveness
under 2D and 3D conditions. These effects were similarly prevented both by treatment with pharmacological
antagonists and by genetic depletion, indicating that not only the P2X7R expression but also its activity is
important in promoting cell invasiveness. These results are in agreement with previous reports performed with
human cancer cells [11–13,15,22,45]. While mechanistic determinants for such a pro-invasive role were not clearly
delineated, we have identified for the first time in this study the P2X7R expression in invadopodial structures
involved in ECM degradation. More specifically, the P2X7R expression enhanced the ECM-degradative activity
of invadopodia, most likely through stimulating release of proteolytic enzymes [12] such as Cath B (Figure 2f),
rather than formation of these structures per se. Activation of the P2X7R also importantly modified cancer cell
morphology and triggered the acquisition of a more aggressive phenotype, characterized by activation of Cdc42
Rho-GTPase, remodelling of F-actin, elongation of cells and formation of filopodia. Taken together, the results
presented in this study strongly suggest the involvement of P2X7R in promoting the acquisition of a mesenchymal
invasive phenotype in mammary cancer cells. Activation of P2X7R led to a reduction in the expression of ZO-1,
which is important in maintaining tight junction function and epithelial polarity. However, in our model, activation
of the P2X7R appears not important in inducing EMT. Indeed, there was no significant change in the expression of
EMT-promoting transcription factors, Zeb1, Snail1 or Twist, and the expression of the gene encoding for E-cadherin
was not modified. The protein expression of the mesenchymal marker vimentin was not modified either. These
findings are different from what are reported in recent studies examining other cancer types. In prostate cancer
cells, P2X7R was shown to promote invasiveness and metastatic properties and silencing its expression attenuated
ATP- or BzATP-induced changes in the expression of EMT-related genes, Snail, E-cadherin and Claudin-1 [15].
In osteosarcoma cells, stimulation of P2X7R reduced the expression of E-cadherin, and induced the expression of
Snail, vimentin and fibronectin. These effects were prevented by pharmacologically antagonizing the P2X7R or
knocking down its expression [45]. However, these differences might depend on the cell types studied and on
their level of transition. Indeed, it was reported that murine 4T1 mammary cancer cells, which are highly invasive
and metastatic, do not strictly exhibit the genotypic and phenotypic properties of EMT [46]. It was postulated that
other processes may govern the metastatic capability of these cells. Furthermore, it is know that EMT is not an
all-or-nothing phenomenon, and some cancer cells display intermediate or partial transition states that have been
identified to be highly aggressive [47].
Here, we investigated the role of P2X7R, whether it was expressed by cancer cells or by host cells, in
mammary cancer progression. By using P2rx7+/+ and P2rx7−/− mice, we demonstrated that, in the syngeneic and
orthotopic model of mammary cancer, there is no participation of the P2X7R in the host organism in either anti-
or pro-tumour activities. Because the level of the anti-tumour response of the host organism might depend on
the size of the primary tumour, we inoculated two different numbers of mammary cancer cells (low density of
1 × 104 or high density of 1 × 106 cells per inoculation site) but no difference was observed. Such a finding is in
apparent contradiction to what were reported by previous studies [39,40], but may be due to the specific mammary
gland microenvironment [48], as compared to the subcutaneous or colic environments, or to specific anti-immune
responses induced by 4T1 cells. Such possibilities should be investigated in further studies. However, in stark
contrast, the expression and activity of P2X7R in mammary cancer cells had a predominant effect in mammary
tumour growth and metastasis development. Loss of the P2rx7 expression in two cell lines derived from 4T1
cells led to a significant delay in primary tumour growth, while the cells demonstrated a slight increase in the
proliferation rate compared to the P2rx7+/+ cells. The consistent results using two different P2rx7-knocked-out
clones rule out possible off-targets of the CRISPR/Cas9 technique used and demonstrate the critical involvement
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of cancer cell invasiveness in primary tumour growth. It is interesting to notice that while knocking out the
expression of P2X7R in 4T1 cells slightly increased their proliferation rate in vitro, it completely abolished the
growth of the primary mammary tumour in vivo. One possible explanation is that, by promoting the proteolytic
degradation of the ECM and local invasion, P2X7R importantly supports primary tumour growth. We also
demonstrated a clear reduction of metastatic colonization of organs when cancer cells did not express the P2rx7
gene. However, it remains unclear whether this effect is specific or due to the important delay in primary tumour
growth. Furthermore, we demonstrated that treatment with specific P2X7 antagonists with different modes of
action, one being competitive (A438079) and the other being non-competitive (AZ10606120), had similar effects in
reducing the tumour growth in wild-type mice.
4. Materials and Methods
4.1. Agonists, Antagonists, Salts and Chemicals
Adenosine 5′-triphosphate (ATP) disodium salt and 2′-(3′)-O-(4-benzoylbenzoyl) adenosine 5′-triphosphate
(BzATP) triethylammonium salt were purchased from Sigma-Aldrich (St. Quentin Fallavier, France) and prepared
in PBS without Ca2+. A438079, AZ10606120 and NF340 were purchased from Tocris Bio-Techne (Noyal Châtillon
sur Seiche, France) and prepared in saline solution. All salts and pH buffers for electrophysiological solutions
were purchased from Sigma-Aldrich. Fluorescent probes (Phalloidin DyLight® 488, DQ™-BSA and Fura2-AM)
were all purchased from Invitrogen (Thermo Fisher Scientific, Villebon-sur-Yvette, France).
4.2. Cells and Cell Culture
Human melanoma cancer cell line MDA-MB-435s-luc (thereafter called “MDA-MB-435s”) was constructed as
previously described [49]. Murine mammary cancer cell line 4T1 from the Balb/c strain was purchased from LGC
Standards (Molsheim, France), and a stable 4T1-luc cell line expressing the luciferase gene (thereafter called “4T1
cells”) was obtained by transduction with lentiviral vectors containing the luciferase gene and blasticidin resistance
gene for selection (GIGA Viral Vectors, Liege, Belgium). stable 4T1 cell lines knocked-out for the expression of
the P2rx7 gene were obtained using the CRISPR/Cas9 technique by transfection with the P2rx7 Double Nickase
Plasmid (Santa Cruz Biotechnology, CliniSciences, Nanterre, France). Clonal selection was performed using
2 µg/mL puromycin. Two clones have been kept for this study, called “Crispr#1” and “Crispr#2”. A null-target
Double Nickase Plasmid was also used to transfect 4T1 cells, leading to the selection of a control cell line, thereafter
called “CTL” cell line. Efficiency of the CRISPR-mediated knock-down was assessed by RT-qPCR and invasion
assays, and stability of clones was followed for a minimal duration of 6 weeks. Selected clones displayed similar
levels of luciferase activity.
MDA-MB-435s cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
5% foetal calf serum (FCS). All 4T1-derived cells were cultured in RPMI medium supplemented with 10% FCS.
Cells were grown at 37 ◦C in a humidified 5% CO2 incubator. Mycoplasma contamination tests were performed
routinely (MycoAlert™ Mycoplasma Detection Kit, Lonza, Thermo Fisher Scientific, Villebon-sur-Yvette, France).
4.3. Small Interfering RNA Transfection
4T1 mammary cancer cells were transfected with siRNA directed against mouse P2rx7 mRNA (siP2X7) or
scrambled siRNA as a control (siCTL), both of which were purchased from Tebu-Bio (Le Perray-en-Yvelines,
France). Cells were transfected with 20 nM siRNA by using Lipofectamine RNAi max (Invitrogen). Experiments
were performed 24 h after transfection and efficacy of silencing was assessed by RT-qPCR.
4.4. RNA Extraction, Reverse Transcription and Polymerase Chain Reaction
For conventional RT-PCR, total RNA was extracted using NucleoSpin® RNA II kit (Macherey Nagel EURL, Hoerdt,
France) and reverse transcribed with PrimeScript™RT Reagent (Ozyme, Saint-Cyr-l’École, France). PCR was performed
with GoTaq® Flexi DNA Polymerase (Promega, Charbonnières-les-Bains, France) according to manufacturer’s
recommendations. PCR products were loaded on 2% agarose gels and visualised after UV excitation.
For quantitative PCR (qPCR), total RNA was extracted using TRIzol™ Reagent (Invitrogen),
and reverse-transcribed with the PrimeScript™ RT Reagent Kit (Ozyme, France). PCR were performed using
SYBR qPCR Premix Ex Taq (Ozyme, France) and CFX CONNECT (Bio-rad, Marnes-la-Coquette, France). All primers
sequences are described in Table 1.
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Table 1. Sequences of conventional Polymerase Chain Reactions (PCR) and quantitative Polymerase Chain Reactions (qPCR) primers and expected amplicon size.
Mouse Genes Applications Corresponding Proteins Forward Primers (5′→3′) Reverse Primers (5′→3′) Amplicon—Expected Size (bp)
Primers for conventional PCR
mP2rx1 PCR P2X1 CCTCAAGTGGCCTTATCAGC GGTACCATTCACCTCCTCCA 467
mP2rx2 PCR P2X2 ACGTTCATGAACAAAAACAAG TCAAAGTTGGGCCAAACCTTTGG 360
mP2rx3 PCR P2X3 GGACGCTATGCCAACAGAGT ACGTCCCCTACCCTCAAGAT 461
mP2rx4 PCR P2X4 GCGTCTGTGAAGACCTGTGA GCCTTTCCAAACACGATGAT 521
mP2rx5 PCR P2X5 TCCCGGATGGCGAGTGTTCAG GATGGGGCAGTAGAGATTGGTGGAG 323
mP2rx6 PCR P2X6 AACTGGGAACATGGCTTCTG CACCAGCTCCAGATCTCACA 516
mP2rx7 PCR P2X7 TGCACATGATCGTCTTTTCC GGCAAGATGTTTCTCGTGGT 532
Primers for qPCR
mP2rx7 qPCR P2X7 AGCACGAATTATGGCACCGT CCCCACCCTCTGTGACATTCT 172
mCDH1 qPCR E-Cadherin CAGTTCCGAGGTCTACACCTT TGAATCGGGAGTCTTCCGAAAA 131
mGusb qPCR β-Glucuronidase TATGGAGCAGACGCAATCCC TTCGTCATGAAGTCGGCGAA 164
mSnai1 qPCR Snail1 CACACGCTGCCTTGTGTCT GGTCAGCAAAAGCACGGTT 133
mTwist qPCR Twist TTCTCGGTCTGGAGGATGGA TCTCTGGAAACAATGACATCTAGG 110
mZeb1 qPCR Zeb1 ACCGCCGTCATTTATCCTGAG CATCTGGTGTTCCGTTTTCATCA 91
mZO1 qPCR ZO1 GCCTCAGAAATCCAGCTTCTCGAA GCAGCTAGCCAGTGTACAGTATAC 194
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4.5. Electrophysiology
Electrophysiological recordings of ATP-induced ionic currents were performed in the whole- cell configuration
of the patch clamp technique. Patch pipettes were pulled from borosilicate glass (World Precision Instruments,
Hitchin, UK) to a resistance of 4–6 MΩ. Currents were recorded under voltage-clamp mode using an Axopatch
200B amplifier (Axon Instrument, Molecular Devices, San Jose, CA, USA) and analogical signals were filtered at
10 kHz and digitized using a 1322A Digidata converter (Molecular Devices, San Jose, CA, USA). Cell capacitance
and series resistance were electronically compensated. Membrane potential was held at −60 mV. Experiments
were performed at room temperature (20–25 ◦C) in extracellular physiological saline solution (PSS in mM:
147 NaCl, 10 N-2-hydroxyethylpiperazine-N′-2ethansulphonic acid (HEPES), 13 D-glucose, 2 KCl, 2 CaCl2
and 1 MgCl2) and pipettes were filled with intracellular saline solution (in mM: 147 NaCl, 10 HEPES and 10
ethylene glycol-bis-(2-aminoethyl ether)-N, N, N′, N′-tetraacetic acid (EGTA) with osmolarity and pH values
of 295–315 mOsm and 7.3, respectively). ATP was externally applied using a RSC160 fast-flow delivery system
(BioLogic Science Instruments, Seyssinet-Pariset, France) for 10 s, at the concentrations indicated in the Figure 1
legend. P2X7 antagonist A438079 was perfused into the bath for 2 min before recording its effect in the presence of
5 mM ATP. ATP concentration-response curves were obtained by first obtaining a maximum response to 10 mM
and then by applying decreasing concentrations of ATP and the results were plotted using Origin Pro 2015
software (Microcal Software Inc., Northampton, MA, USA). EC50 was derived by fitting the data to Hill equation
provided by the software.
4.6. Intracellular Ca2+ Measurement
ATP- and BzATP-induced increases in intracellular Ca2+ levels were measured using ratiometric fluorescent
probe Fura2-AM and a Flexstation3 microplate reader (Molecular Devices) as previously described [25]. Cells were
incubated with 1 µM Fura2-AM for 45 min in OptiMEM medium at 37 ◦C prior to conduct recordings. Cells were
washed and then pre-incubated in the extracellular saline solution (in mM: 147 NaCl, 2 KCl, 1 MgCl2, 10 HEPES
and 13 D-glucose, pH 7.4) with and without 3 mM CaCl2. F340/F380 defined the ratio of the fluorescence intensity
excited alternatively at 340 nm and 380 nm and emitted at 510 nm and was used to indicate the free intracellular
Ca2+ concentration. 3 mM ATP or 0.3 mM BzATP was applied to cells after the baseline was established.
Antagonists, A438079 (10 µM) or AZ10606120 (300 nM) were added 5 min before application of agonist.
4.7. Cell Viability
The effects of exposure to ATP and BzATP at doses indicated in the figure legends for 24 h on 4T1 cell viability
were evaluated by using the tetrazolium salt assay (MTT) as previously described [12]. Briefly, cells were treated
with increasing doses of ATP and BzATP for 24 h and cell viability was measured after incubation with MTT for
40 min at 37 ◦C.
4.8. Cell Adhesion
To assess 4T1 cancer cell adhesion, 2 × 104 cells were seeded in their normal culture medium in wells of a
96-well plate and placed in the incubator for 30 min at 37 ◦C and 5% CO2. After one wash in PBS, the number of
adherent cells was evaluated in wells using the MTT assay.
4.9. Two- and Three-Dimensions In Vitro Invasion Assays
2-D cancer cell invasiveness was measured as previously described [12] using 8 µM pore-size polyethylene
terephtalate membrane inserts covered with Matrigel™ matrix (Becton Dickinson, Le Pont de Claix, France).
Cells at the lower surface of the insert were stained with DAPI and nuclei were counted after collecting pictures
with a Nikon TI-S microscope (Nikon S.A.S., Champigny-sur-Marne, France). Results were normalized to the
control condition in the absence of agonist or antagonist.
For 3D invasiveness assays, cancer cell spheroids were used. To do so, 500 4T1 cells or 2000 MDA-MB-435s
cells were seeded in wells of ultra-low attachment 96-well plates (Corning, Boulogne-Billancourt, France). After
allowing spheroid formation at 37 ◦C and 5% CO2 in the incubator for 24 h for 4T1 and 48 h for MDA-MB-435s,
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4 mg/mL Matrigel™ was added to the wells, in the absence or presence of 0.3 mM BzATP, and 10 µM A438079.
3D-Matrigel invasion by spheroids was followed every hour using a Nikon TI-S microscope. Invasion distance
and spheroid circularity were measured and calculated using ImageJ version 1.48.
4.10. Invadopodia Activity Assay
Invadopodia activity was assessed by culturing cells for 24 h on the top of a layer of Matrigel™ (4 mg/mL)
matrix containing 50 µg/mL of DQ-BSA in LabTeck™ (Palaiseau, France) chambers, as previously reported [26].
Briefly, cells were fixed in 4% paraformaldehyde for 15 min, permeabilized using 0.02% saponin for 20 min and
incubated with 3% bovine serum albumin (BSA) for 30 min. F-actin was stained with 1.5 units/mL Phalloidin
DyLight 488 (Invitrogen). Slides were mounted using ProLong® Gold Antifade Mountant with DAPI (Invitrogen).
Epifluorescence microscopy was performed with a Nikon TI-S (Nikon). Co-localized pixels for DQ-BSA and
Phalloidin-488 were obtained using NIS-Element (Nikon) and fluorescence intensity, as well as the number of
invadopodia, was quantified with ImageJ.
4.11. Invadopodia Fractionation
Invadopodia, which were embedded in the gelatin matrix, were separated from cellular bodies using the
previously described protocols [26]. Briefly, cells were grown on the top of a 2%-gelatin matrix. Cellular bodies
were removed using osmotic shock and further fractionated to isolate a “cytosolic” and an “all membranes”
fractions. Proteins from invadopodia were solubilised in a lysis buffer containing 0.1% NP-40 and 1 mM DTT
and separated from gelatin by centrifugation at 17,000× g for 30 min. Proteins in each fraction were separated
according to standard SDS-PAGE protocols on 8% and 12% polyacrylamide gels and then transferred on PVDF
membrane. Primary antibodies used were: mouse anti-HSC70 (sc-7298 Santa Cruz Biotechnology, Inc., Heidelberg,
Germany), rabbit anti-caveolin 1 (sc-894 Santa Cruz Biotechnology, Inc., Germany), rabbit anti-β-adaptin (610382
BD Biosciences, Le Pont de Claix, France), cathepsin B (20-CR71 Fitzgerald, Acton, MA, USA), cortactin (05-180
Millipore, Guyancourt, France), FAK (036SC-558 Santa Cruz Biotechnology, Inc., Heidelberg, Germany), P2X7
(APR-008 Alomone Labs Ltd., Jerusalem, Israel). Secondary HRP-conjugated antibodies were: goat anti-mouse
(Santa Cruz Biotechnology, Inc., Heidelberg, Germany), goat anti-rabbit (Jackson Immunoresearch Interchim,
Montluçon, France), rabbit anti-β-actin-HRP (Santa Cruz Biotechnology, Inc., Heidelberg, Germany). Densitometric
analyses were performed using ImageJ. Full uncropped blots are shown in Figures S5 and S6.
4.12. Epifluorescence Experiments
Cells were grown for 24 h in LabTeck™ chambers on a layer of Matrigel matrix (4 mg/mL) containing
50 µg/mL of DQ-BSA. Cells were fixed in 4% paraformaldehyde for 15 min and then incubated with 3% BSA
for 30 min. P2X7 was immunodetected using a primary antibody (APR-008, Alomone Labs Ltd., Israel) and a
secondary anti-rabbit IgG AlexaFluor488 (Invitrogen, France). For actin cytoskeleton analysis, cells were grown
on glass coverslips until 40% confluency and then serum was reduced to 1% for 24 h and 0% for 24 h. Cells were
treated with BzATP for 2, 4, 6, 12, 30 min and 24 h. Cells were fixed in 4% paraformaldehyde for 15 min,
permeabilized with 0.1% triton-X-100 for 5 min, incubated with 3% BSA for 30 min and stained with 1.5 units/mL
Phalloidin DyLight® 488 (Invitrogen, France) for 1 h. Slides were mounted using ProLong® Gold Antifade
Mountant with DAPI (Invitrogen, France). For the analysis of filopodia, cells were transfected with Ibidi® LifeAct
plasmid (Generously provided by Laurent Counillon, CNRS UMR7370, University of Nice-Sophia Antipolis, Nice,
France) using TransIT®-2020 (Mirus Euromedex, Souffelweyersheim, France). Epifluorescence and time-lapse
microscopy was performed with a Nikon TI-S (France) (see Videos S1–4). Numbers of filopodia formed per hour
and filopodia velocity were quantified using the Adapt plugin for ImageJ.
4.13. RhoGTPases Pull-Down Assays
The activity of RhoA, Rac1 and Cdc42 was assessed using pull-down assays according to the manufacturer’s
protocols (Cat BK030 RhoA/ Rac1/Cdc42 Activation Assay Combo Biochem Kit, Cytoskeleton, Tebu-Bio, France)
as previously described [50]. Briefly, cells were grown until 40% confluency in 75 cm2 flasks in normal growing
medium, and serum was reduced to 1% for 24 h and 0% for 24 h. After treatment with 0.3 mM BzATP with
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or without 10 µM A438079 for 30 min in culture medium without serum, cells were lysed and samples were
snap-frozen in liquid nitrogen. For each condition, 500 µg total lysates were used for pull-down assay according to
the manufacturer’s instructions and then used for western blotting (Full uncropped blots are shown in Figure S7).
4.14. Western-Blotting Experiments
Cells were washed twice with PBS and lysed in presence of a lysis buffer (50 mM Tris, pH 7, 100 mM NaCl,
5 mM MgCl2, 10% glycerol, 1 mM EDTA), containing 1% Triton-X-100 and protease inhibitors (Sigma-Aldrich,
France). Cell lysates were cleared by centrifugation at 16,000× g for 10 min. Total protein concentrations were
determined using the Pierce® BCA Protein Assay Kit (Thermofisher Scientific, Villebon-sur-Yvette, France).
Protein sample buffer was added and samples were boiled at 100 ◦C for 3 min. Samples were loaded (20 µg of total
proteins for cell lysates and 6 µL of concentrated supernatants) and electrophoretically separated on 10% or 12%
polyacrylamide gels and then transferred to polyvinylidene difluoride membranes. Vimentin was detected using
a primary anti-vimentin rabbit antibody (1/1000, clone D21H3, Cell Signaling Technology, Danvers, MA, USA)
and a secondary horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG antibody at 1:2000 (TEBU-BIO,
Le Perray-en-Yvelines, France). E-cadherin was detected using a monoclonal mouse primary antibody (1/1000,
HECD-1, 13-1700 ThermoFisher Scientific) and a secondary HRP-conjugated anti-mouse-IgG secondary antibody
at 1:2000 (TEBU-BIO). β-actin was used as a sample loading control using anti-β-actin-HRP primary antibody
at 1:1000 (C4, Santa Cruz Biotechnology ref sc-47778). Western blot experiments for the detection of both pro
and mature forms of cathepsin B were performed from 4T1 concentrated supernatants. Cells were grown to 80%
confluence in a 6-well plate. After 24 h treatment (BzATP ± A438079) in Optimem medium (Invitrogen, France),
cell supernatants were taken and concentrated using 10,000 MWCO filters (Merck Millipore, Molsheim, France).
Cathepsin B proteins were visualized using polyclonal rabbit anti-human cathepsin B primary antibodies (1/150,
Fitzgerald) and a goat anti-rabbit horseradish peroxidase (HRP)-conjugated secondary antibody (1/5000).Proteins
were revealed using electrochemiluminescence-plus kit (Pierce ECL Western Blotting Substrate, ThermoFisher
Scientific, France) and captured on a PXi acquisitions system (SYNGENE, Cambridge, UK). Densitometry analysis
of protein bands was performed using the Gel Tool from Fiji software (Scientific image analysis software available
at https://fiji.sc). Full uncropped blots are shown in Figures S5 and S6.
4.15. In Vivo Mammary Cancer Model and Experiments
All experiments have been approved by the Comité d’éthique du Centre-Val de Loire (Comité d’éthique en
expérimentation animale Campus CNRS d’Orléans n◦3, Ref 005377.01 Apafis #12960) and were performed in
accordance with the European Ethics rules. All animals were bred and housed in isolated ventilated cages at the
CNRS UPS44—TAAM-CIPA (CNRS Campus, Orléans, France), in controlled conditions with a 12 h light/dark
cycle at 22 ◦C, and food and water ad libitum. We developed a syngeneic and orthotopic mouse mammary cancer
model in female BALB/cJ immunocompetent mice. To do so, 4T1-luciferase-expressing mouse mammary cancer
cells were injected into the fifth mammary fat pad of 6 weeks-old mice. The luciferase activity was mainly used to
follow secondary tumour appearance and growth in vivo, subsequent to D-luciferin (150 mg/kg) intraperitoneal
injection and bioluminescent imaging (IVIS Lumina II, Perkin Elmer, Villebon-sur-Yvette, France). Primary tumour
volume (mm3) and growth over time were most effectively measured with a calliper, twice a week, and calculated
as (L × l2)/2 (in mm). Metastases were counted macroscopically at the completion of studies, during autopsies.
Animal weight was measured once a week.
In experiments comparing the role of the number of injected cells on primary tumour growth, in mice
expressing the P2rx7 gene or not, cell suspensions of either 1 × 106 or 1 × 104 4T1-luc derived CTL (P2rx7+/+)
cancer cells were injected to BALB/cJ mice P2rx7−/− (Generously provided by Niklas Rye Jørgensen, Department
of Clinical Biochemistry, Rigshospitalet, Glostrup, Denmark) or to BALB/cJ P2rx7+/+ litter mate control mice,
which were housed in the same environmentally controlled conditions. P2rx7−/− mice were backcrossed onto the
BALB/cJ background as previously described [51].
In experiments assessing the effect of P2rx7 gene expression in mammary cancer cells on primary tumour
growth and metastatic progression, 1 × 104 CTL (P2rx7+/+), Crispr#1 or Crispr#2 (P2rx7−/−) 4T1-derived mammary
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cancer-cells (see Section 4.2) in 100 µL of a PBS solution were injected in the mammary fat pad, under isoflurane
anaesthesia, of wild-type BALB/cJ mice (Janvier Labs, Saint Berthevin, France).
In experiments assessing the efficacy of P2X7 antagonism, 1 × 104 CTL (P2rx7+/+) cells were injected
in the mammary fat pad of wild-type BALB/cJ mice (Janvier Labs, Saint Berthevin, France), and treatments
were randomly administrated once tumours reached 80 mm3. Then, 230 µL of 3 mg/mL A437079 or 100 µL of
300 nM AZ10606120 were injected intraperitoneally every two days. Primary tumours were fixed in formalin,
included in paraffin, and cut in 5 µM tissue sections. Slides were deparaffinized, rehydrated and heated in
citrate buffer pH 6.0 for antigenic retrieval. Immunohistochemistry was performed using a primary antibody
anti-P2X7 (APR-008 Alomone Labs Ltd.) and streptavidin-biotin-peroxidase method with diaminobenzidine as the
chromogen (Kit LSAB, Dakocytomation, Dako France SAS, Les Ullis, France). Slides were finally counterstained
with haematoxylin. Negative controls were obtained by omission of the primary antibody or incubation with an
irrelevant antibody.
4.16. Mathematical Model for Assessing Mammary Tumour Growth Depending on Treatments
A Gompertz model was used to describe mammary tumour growth over time. This model included three
parameters, i.e., the first-order growth rate constant (kgrowth), the maximum tumour volume (Vmax) and the power
coefficient γ. In addition, the effect of treatment (EFF) on tumour volume was estimated as a parameter being 0
without treatment (i.e., before treatment, in both A438079 and AZ10606120 groups, and every time in the vehicle
group) and estimated when treatment was administered. Model parameters were estimated using nonlinear
mixed-effects modelling. This approach allows description of the inter-subject variability in the population (mean
and inter-subject standard deviations) and quantification of the association of factors of variability (referred
as covariates) with inter-subject distribution of Gomperz parameters. The influence of treatment condition
(A438079 or AZ10606120) was tested as a covariate on both kgrowth and Vmax. This analysis was carried out using
MonolixSuite2018 (Lixoft®, Antony, France). The effects of treatment and treatment conditions on each parameter
were tested using the likelihood ratio test (LRT).
4.17. Data Presentation and Statistical Analysis
Data are displayed as median (n = number of cells/ independent experiments). Two-way ANOVA followed
by a Dunn’s Multiple Comparison Test, Wilcoxon Signed Rank Test and Mann-Whitney rank sum test were used
to compare different conditions, as indicated in the figure legends. Statistical significance is indicated as: * p < 0.05;
** p < 0.01 and *** p < 0.001. NS stands for not statistically different.
5. Conclusions
In this study, we have revealed the P2X7R in mammary cancer cells as a key molecular determinant of cancer
cell invasiveness and mammary tumour growth, and as a possible target for pharmacological interventions.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/9/2342/s1:
Figure S1: P2X7R receptor is functional in 4T1 mammary cancer cells; Figure S2: P2X7R receptor promotes 3D
cancer cell invasiveness of MDA-MB435s human cancer cells; Figure S3: P2X7R receptor promotes invadopodial
activity of extracellular matrix degradation in MDA-MB-435s human cancer cells; Figure S4: Antagonism of P2X7R
reduces primary tumour growth; Figure S5: Full and uncropped blots shown in Figure 2b,f; Figure S6: Full and
uncropped blots shown in Figure S3a; Figure S7: Full and uncropped blots shown in Figure 3d,f; Video S1: Control
condition in absence of agonist or antagonist (vehicle); Video S2: stimulation with 300 µM BzATP; Video S3:
incubation with 10 µM A438079; Video S4: incubation with 300 µM BzATP in the presence of 10 µM A438079.
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